| Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. | |
| | |
MedLine Citation:
|
PMID: 18620853 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The Inhaled Steroids in Obstructive Lung Disease (ISOLDE) study was a trial that randomised 752 patients with moderate to severe COPD to fluticasone propionate 1000 mcg/day or placebo for three years. We aimed to examine the causes of death of the ISOLDE participants after the original three up to 13 years post-randomisation. Death certificates were obtained either from the NHS Strategic Tracing Service or from the Office of National statistics. Deaths were classified according to the trial protocol. In the subsample of 375 participants from the seven ISOLDE original centers where complete extended follow-up was conducted, the factors associated with observed higher mortality (p<0.05) were male gender, older age and more severe COPD. Causes of death were; 107 (52%) respiratory, 38 (18%) cardiac, 29 (14%) lung cancer, 16 (8%) other cancer and 16 (8%) other causes. The percentage of respiratory-related deaths increased during the follow-up period; from 46% within the three-year trial, to 48% after 3-6 years, 57% after 6-9 years, and 60% after 9-13 years of follow-up (p for trend<0.05). We conclude that participants' survival is poor (only 44% in the 13 years after the ISOLDE trial), and that respiratory-related illnesses were the most frequent causes of death in patients with moderate to severe COPD. |
| | |
Authors:
|
Geraldine Bale; Pablo Martínez-Camblor; P Sherwood Burge; Joan B Soriano |
Related Documents
:
|
14586043 - Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstruc... 16456383 - Use of theophylline in chronic obstructive pulmonary disease: examining the evidence. 20851843 - Does intravenous {delta}9-tetrahydrocannabinol increase dopamine release? a spet study. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2008-07-14 |
Journal Detail:
|
Title: Respiratory medicine Volume: 102 ISSN: 1532-3064 ISO Abbreviation: Respir Med Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-02 Completed Date: 2009-05-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8908438 Medline TA: Respir Med Country: England |
Other Details:
|
Languages: eng Pagination: 1468-72 Citation Subset: IM |
Affiliation:
|
Respiratory Medicine, Birmingham Heartlands Hospital, Birmingham, UK. geraldine.bale@heartofengland.nhs.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Aged Androstadienes / therapeutic use Female Follow-Up Studies Humans Kaplan-Meiers Estimate Lung Diseases / mortality Male Middle Aged Prognosis Pulmonary Disease, Chronic Obstructive / drug therapy, mortality* Randomized Controlled Trials as Topic Risk Sex Factors Smoking |
| Chemical | |
Reg. No./Substance:
|
0/Androstadienes; 90566-53-3/fluticasone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Next Document: Urban observatories opportunities for environmental monitoring: solid wastes.